Novartis Investigative Site

Harrow, Middlesex HA1 3UJ

1 studies enrolling now · 5 studies all time

What they study most

Cardiovascular Disease and Lipoprotein(a), Heart Failure With Preserved Ejection Fraction, Primary Bile Acid Diarrhea, Primary Prevention of Atherosclerotic Cardiovascular Disease

Studies at this site

• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea. — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed